

MICROVENTION AWARDED TWO NEW PATENTS FOR STROKE AND ANEURYSM TREATMENT

Company Continues to Broaden Intellectual Property Position

ALISO VIEJO, Calif. March 9, 2004 -- MicroVention, Inc., a leading developer, manufacturer and marketer of minimally invasive treatments for cerebral vascular diseases, announced today that the U.S. Patent and Trademark Office has awarded the company two U.S. Patents; No. 6,685,722 entitled "Embolectomy catheters and methods for treating stroke and other small vessel thromboembolic disorders," and No. 6,689,141 entitled "Mechanism for the deployment of endovascular implants."

MicroVention President and Chief Executive Officer Mike Kleine said, "We continue to work diligently on building our intellectual property assets and are pleased to add these two patents to our portfolio of over 20 issued in the U.S. and internationally. In the past year, the company has been awarded several key patents for both embolectomy and embolization technologies. These and other proprietary technologies will allow the company to maintain its leadership position as an innovator in two large markets cerebral aneurysms and acute stroke. We were particularly pleased to strengthen the coverage of our HydroLink Detachment System. This system is used throughout our embolization product lines, including our platinum MicroPlex Coil System and our next-generation HydroCoil Embolic System."

The HydroCoil Embolic System (HES) is a unique embolization device combining the company's platinum microcoil technology with a highly expandable microporous hydrogel called Intelligel. Intelligel is a responsive or "smart material" that remains inactive until it comes in contact with the pH of blood. This gives physicians the ability to precisely control delivery of the device and allows for repositioning if necessary. The HES combines the safety and ease of use of platinum coils with the filling and healing properties of the hydrogel. HES offers a new therapeutic alternative to the current treatment choices of platinum coil embolization and neurosurgical clipping. Platinum coils have been used for aneurysm embolization for approximately 12 years since that technology was introduced by Target Therapeutics, now a division of Boston Scientific.

Endovascular embolization is one of the fastest growing markets in vascular medical technology. Growth has been fueled by recent clinical data from the International Subarachnoid Aneurysm Trial (ISAT), published in *The Lancet* journal, and other clinical research demonstrating the benefits of less-invasive endovascular treatment of aneurysms.

"We are poised to benefit from the worldwide shift to endovascular embolization for the treatment of aneurysms. When you combine this trend with the technology-driven growth and positive demographics of our patient markets, we believe MicroVention's technology is very well positioned for significant adoption within the neurointerventional and neurosurgical communities," added Kleine.

About MicroVention, Inc.

Microvention, Inc. (www.microvention.com) is a privately held medical-device company dedicated to the development and commercialization of new catheter-based technologies for the endovascular treatment of peripheral and cerebral vascular diseases. The company has received 510(k) clearance and CE Mark for both its MicroPlex Coil System and the HydroCoil Embolization System, its next-generation endovascular coil system designed to treat cerebral aneurysms. MicroVention sells its products through its direct sales force in the U.S., Canada, France, Germany and the United Kingdom and through distributors in various other countries.

MicroVention Contacts:

Michael Kleine, President, CEO
William Hughes, Vice President, CFO
Ph. 949-461-3314
Fx. 949-461-3329

Matt Clawson (Media)
Allen & Caron, Inc.
Ph. 949-474-4300
Fx. 949-474-4330